Next Article in Journal
Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group
Next Article in Special Issue
Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles
Previous Article in Journal
Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors
Previous Article in Special Issue
Tumor Neovascularization and Developments in Therapeutics
Open AccessArticle

An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer

Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site, 72076 Tuebingen, Germany
DFG Cluster of Excellence 2180 “Image-guided and Functional Instructed Tumor Therapy (iFIT)”, 72076 Tuebingen, Germany
Department for Immunology, Eberhard Karls University, 72076 Tuebingen, Germany
Department of Hematology and Oncology, Eberhard Karls University, 72076 Tuebingen, Germany
Author to whom correspondence should be addressed.
These authors have contributed equally to this work.
Cancers 2019, 11(6), 789;
Received: 13 May 2019 / Revised: 28 May 2019 / Accepted: 5 June 2019 / Published: 7 June 2019
The introduction of monoclonal antibodies (mAbs) has largely improved treatment options for cancer patients. The ability of antitumor mAbs to elicit antibody-dependent cellular cytotoxicity (ADCC) contributes to a large extent to their therapeutic efficacy. Many efforts accordingly aim to improve this important function by engineering mAbs with Fc parts that display enhanced affinity to the Fc receptor CD16 expressed, e.g., on natural killer (NK) cells. Here we characterized the CD133 mAb 293C3-SDIE that contains an engineered Fc part modified by the amino acid exchanges S239D/I332E—that reportedly increase the affinity to CD16—with regard to its ability to induce NK reactivity against colorectal cancer (CRC). 293C3-SDIE was found to be a stable protein with favorable binding characteristics achieving saturating binding to CRC cells at concentrations of approximately 1 µg/mL. While not directly affecting CRC cell growth and viability, 293C3-SDIE potently induced NK cell activation, degranulation, secretion of Interferon-γ, as well as ADCC resulting in potent lysis of CRC cell lines. Based on the preclinical characterization presented in this study and the available data indicating that CD133 is broadly expressed in CRC and represents a negative prognostic marker, we conclude that 293C3-SDIE constitutes a promising therapeutic agent for the treatment of CRC and thus warrants clinical evaluation. View Full-Text
Keywords: colorectal cancer; immunotherapy; antibody; NK cells; ADCC; CD133; prominin-1 colorectal cancer; immunotherapy; antibody; NK cells; ADCC; CD133; prominin-1
Show Figures

Figure 1

MDPI and ACS Style

Schmied, B.J.; Riegg, F.; Zekri, L.; Grosse-Hovest, L.; Bühring, H.-J.; Jung, G.; Salih, H.R. An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer. Cancers 2019, 11, 789.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop